Janux Therapeutics, Inc.
Q3 2024 13F Holders
Symbol
JANX
CUSIP
47103J105
Type
Equity
Class
COM
Num filings
171
Total reported value, excl. options
$2.07 B
Compare 2024 Q3 to
2025 Q2
2025 Q1
2024 Q4
2024 Q2
2024 Q1
2023 Q4
2023 Q3
2023 Q2
2023 Q1
2022 Q4
2022 Q3
2022 Q2
2022 Q1
2021 Q4
2021 Q3
2021 Q2
Manager
Report Date
Value ($000)
Shares
Option Type